Trade

with

Dendreon Corp
(NASDAQ: DNDN)
AdChoices
1.03
-0.01
-0.96%
After Hours :
1.02
-0.01
-0.97%

Open

1.03

Previous Close

1.04

Volume (Avg)

1.03M (2.33M)

Day's Range

1.00-1.05

52Wk Range

0.8898-3.52

Market Cap.

166.73M

Dividend Rate ( Yield )

-

Beta

2.53

Shares Outstanding

160.31M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Underperform
    • Revenue

    • 283.75M

    • Net Income

    • -296.80M

    • Market Cap.

    • 166.73M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -70.66

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 2.53

    • Forward P/E

    • -2.36

    • Price/Sales

    • 0.54

    • Price/Book Value

    • -0.55

    • Price/Cash flow

    • -1.45

      • EBITDA

      • -211.62M

      • Return on Capital %

      • -44.10

      • Return on Equity %

      • -

      • Return on Assets %

      • -44.10

      • Book Value/Share

      • -1.87

      • Shares Outstanding

      • 160.31M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Underperform
        • 1 Year Price Target

        • 0.92

        • Credit Rating

        • CCC

        • Analysts

        • 8

        • EPS Estimate

        • -0.44

        • Cashflow Estimate

        • -0.10

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 12.10

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 380.31

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 47.71

            • 82.75

            • Pre-Tax Margin

            • -70.66

            • 39.38

            • Net Profit Margin

            • -70.66

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 53.10

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -43,844.00

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 3.21

              • 2.92

              • Quick Ratio

              • 2.14

              • 2.35

              • Interest Coverage

              • -2.85

              • 38.02

              • Leverage Ratio

              • -

              • 2.21

              • Book Value/Share

              • -1.87

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -0.77

                • 217.39

                • P/E Ratio 5-Year High

                • -42.52

                • 634.30

                • P/E Ratio 5-Year Low

                • -0.66

                • 124.82

                • Price/Sales Ratio

                • 0.54

                • 9.52

                • Price/Book Value

                • -0.56

                • 8.61

                • Price/Cash Flow Ratio

                • -1.45

                • 50.51

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -

                    (-)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -44.10

                    (-50.90)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -

                    (-)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • 1.90

                  • 1.48

                  • Asset Turnover

                  • 0.62

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -243.03M
                  Operating Margin
                  -85.65
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -1.45
                  Ownership

                  Institutional Ownership

                  32.55%

                  Top 10 Institutions

                  24.20%

                  Mutual Fund Ownership

                  14.21%

                  Float

                  97.81%

                  5% / Insider Ownership

                  5.05%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Vanguard Total Stock Mkt Idx

                  •  

                    2,531,035

                  • 0.00

                  • 1.58

                  • iShares Russell 2000 (AU)

                  •  

                    2,380,806

                  • -1.46

                  • 1.07

                  • Vanguard Capital Opportunity Fund

                  •  

                    2,300,000

                  • 0.00

                  • 1.44

                  • iShares Nasdaq Biotechnology

                  •  

                    2,073,906

                  • -0.47

                  • 0.93

                  • Vanguard Extended Market Index Fund

                  •  

                    1,641,653

                  • 3.22

                  • 1.02

                  • Vanguard Small Cap Index

                  •  

                    1,343,688

                  • -49.26

                  • 0.84

                  • iShares Russell 2000 Growth

                  •  

                    1,129,759

                  • 0.34

                  • 0.51

                  • Vanguard Small Cap Growth Index Fund

                  •  

                    890,205

                  • -50.47

                  • 0.56

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    827,540

                  • 0.00

                  • 0.52

                  • Selectra J. Lamarck Biotech

                  •  

                    760,000

                  • 0.00

                  • 0.47

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Vanguard Group, Inc.

                  •  

                    10,844,707

                  • +12.29%

                  • 6.77

                  • State Street Corp

                  •  

                    9,510,384

                  • +10.80%

                  • 5.94

                  • BlackRock Fund Advisors

                  •  

                    5,867,267

                  • -0.11%

                  • 3.66

                  • PRIMECAP Management Company

                  •  

                    2,901,800

                  • -5.47%

                  • 1.81

                  • Government Pension Fund of Norway - Global

                  •  

                    2,845,740

                  • +393.67%

                  • 1.91

                  • Northern Trust Investments, N.A.

                  •  

                    1,841,201

                  • -10.72%

                  • 1.15

                  • Scopia Management Inc.

                  •  

                    1,824,183

                  • 0.00%

                  • 1.14

                  • Fidelity Management and Research Company

                  •  

                    1,155,080

                  • -4.91%

                  • 0.72

                  • D. E. Shaw & Co LP

                  •  

                    909,067

                  • -47.66%

                  • 0.57

                  • Geode Capital Management, LLC

                  •  

                    854,784

                  • +0.92%

                  • 0.53

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Distressed

                  Style

                  Small Core

                  Dendreon Corp is a Delaware corporation. The Company is a biotechnology company focused on the discovery, development and commercialization of novel therapeutics that improve cancer treatment options for patients. Its product portfol...moreio includes active cellular immunotherapy and small molecule product candidates to treat a range of cancers. PROVENGE(r) (sipuleucel-T), is its first commercialized product licensed by the United States Food and Drug Administration, and is a first in class autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic, metastatic, castrate-resistant (hormone-refractory) prostate cancer. Prostate cancer is the most common non-skin cancer among men in the United States, with over one million men currently diagnosed with the disease, and the se...morecond cause of cancer deaths in men in the United States. The Company owns worldwide rights for PROVENGE. The Other potential product candidates we have under development include our investigational active cellular immunotherapy, DN24-02, which potentially may be used for the treatment of patients with bladder, breast, ovarian and other solid tumors expressing HER2/neu. In addition, the Company has developed an orally-available small molecule treatment targeting TRPM8 that could be applicable to multiple types of cancer. The Company currently depends on specialized vendor relationships that are not readily replaceable for some of the components for its active immunotherapy candidates. Products such as chemotherapeutics, androgen metabolism or androgen receptor antagonists, endothelin A receptor antagonists, antisense compounds, angiogenesis inhibitors and gene therapies for cancer are also under development by a number of companies and could potentially compete with PROVENGE and its other product candidates. The Company’s competitors include major pharmaceutical companies. The Company is subject to a variety of federal, state and local regulations relating to the use, handling, storage and disposal of hazardous materials, including chemicals and radioactive and biological materials. The Company is also subject to regulation by the Occupational Safety and Health Administration (‘OSHA’), and the Environmental Protection Agency (‘EPA’), and to regulation under the Toxic Substances Control Act.lessless

                  Key People

                  W. Thomas Amick

                  President/CEO/Director

                  Douglas G. Watson

                  Director/Chairman of the Board

                  Mr. Gregory Cox

                  CFO/Chief Accounting Officer/Treasurer/Vice President

                  Andrew Seth Sandler

                  Chief Medical Officer/Executive VP

                  Robert Crotty

                  General Counsel/Secretary/Executive VP

                  • Dendreon Corp

                  • 1301 2nd Avenue

                  • Seattle, WA 98101

                  • USA.Map

                  • Phone: +1 206 256-4545

                  • Fax: +1 206 256-0571

                  • dendreon.com

                  Incorporated

                  0

                  Employees

                  710

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: